Revolution Medicines/$RVMD
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Revolution Medicines
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
- Ticker
- $RVMD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 883
- Headquarters
- Redwood City, United States
- Website
- www.revmed.com
RVMD Metrics
BasicAdvanced
$42B
-
-$9.14
1.43
-
Price and volume
Market cap
$42B
Beta
1.43
52-week high
$224.31
52-week low
$58.91
Average daily volume
2.2M
Financial strength
Current ratio
8.36
Quick ratio
8.161
Long term debt to equity
0.501
Total debt to equity
0.504
Interest coverage (TTM)
-20.62%
Profitability
EBITDA (TTM)
-1,675.139
Gross margin (TTM)
-634.59%
Net profit margin (TTM)
-946.82%
Operating margin (TTM)
-852.98%
Effective tax rate (TTM)
0.13%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
-32.13%
Return on equity (TTM)
-93.56%
Valuation
Price to revenue (TTM)
199.198
Price to book
17.31
Price to tangible book (TTM)
17.83
Price to free cash flow (TTM)
-27.313
Free cash flow yield (TTM)
-3.66%
Free cash flow per share (TTM)
-7.04
Growth
Earnings per share change (TTM)
75.99%
3-year revenue growth (CAGR)
96.17%
3-year earnings per share growth (CAGR)
40.29%
What the Analysts think about RVMD
Analyst ratings (Buy, Hold, Sell) for Revolution Medicines stock.
Analyst projections of the future price of Revolution Medicines stock.
Bulls say / Bears say
The FDA approved RASONQUE for previously treated metastatic pancreatic cancer after Phase 3 data showed median overall survival of 13.2 months versus 6.7 months with chemotherapy. That gives Revolution Medicines an approved medicine backed by a substantial survival benefit in a serious cancer. (Revolution Medicines, Revolution Medicines)
RASONQUE generated $197.6 million in US product revenue in the third quarter, despite being available for only about five weeks, and more than 5,000 patients received it commercially. This provides an early sign of meaningful demand for the new treatment. (Revolution Medicines)
The company is testing its RAS medicines in additional settings, including Phase 3 trials for first-line and adjuvant pancreatic cancer and a lung-cancer trial expected to read out in 2027. Positive results could extend growth beyond the current pancreatic-cancer approval. (Revolution Medicines)
RASONQUE’s response rates varied by tumour subtype: the rate was 24% in G12D cancers and 7% in G12R cancers, below chemotherapy’s 14% in G12R. The smaller subgroup analyses have wide uncertainty, so the overall survival result may not translate equally across patients. (Fierce Pharma, Revolution Medicines)
The company reported a $407.5 million quarterly net loss and $417.1 million in research and development expenses, both higher than a year earlier. Product sales have begun, but the large development spend means sustained growth in revenue will be important to fund its plans. (Revolution Medicines)
The first-quarter sales figure may overstate the ongoing launch pace: it included patients moving from an expanded-access programme, a backlog of waiting patients and initial channel stocking. Management also expects gross-to-net discounts to rise as payer mix and discounts develop. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
RVMD Financial Performance
Revenues and expenses
RVMD Earnings Performance
Company profitability
Upcoming events
No upcoming events
RVMD News
AllArticlesVideos
Funds containing RVMD
AllUSDEURGBP
Fund name | Fund size | $RVMD weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 2.65% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 2.50% |
Vanguard FTSE Global Small-Cap$VSMU | $15M | 0.40% |
Vanguard FTSE Global Small-Cap£VSML | $15M | 0.40% |
Xtrackers S&P 500 Swap£XSPX | $9.7B | 0.33% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.